Novo Nordisk Clayton
Clayton, NC | Pharma
12-Month Risk Trend
Monthly scores calculated from weighted factor assessments. Historical data reflects month-end evaluations.
Risk Score Breakdown
Four equally-weighted factors. Workforce and power/grid constraints embedded within. Confidence interval reflects data recency and source reliability.
Score Change Log
Audit trail of risk score changes with rationale. Full derivation notes available upon request.
| Date | Old | New | Change | Rationale |
|---|---|---|---|---|
| Jan 2026 | -- | -- | -- | Monthly review; see RAID log for details |
Contact info@hccouncil.org for detailed factor-by-factor scoring derivation.
Key Risks
Novo Nordisk is expanding manufacturing capacity to address Wegovy and Ozempic supply shortages. Novo Holdings acquired Catalent for $16.5B (completed December 2024), with Novo Nordisk taking three fill-finish facilities for $11B: Bloomington, Indiana (USA), Anagni (Italy), and Brussels (Belgium). U.S.-specific investments include a $4.1B expansion in Johnston County, North Carolina (announced June 2024), the largest life sciences investment in NC history. Production of semaglutide-based GLP-1 drugs is ramping throughout 2024-2025. Novo Nordisk is the world's largest maker of diabetes and obesity medications with 2,500+ NC employees. (Sources: Novo Nordisk Press Release Feb 2024, Jun 2024; NC Biotech Center; BioPharma Dive Dec 2024)
RAID Log
Risk assessments reviewed monthly. Last review: Jan 9, 2026
| Risk | Impact | Probability | Mitigation |
|---|---|---|---|
| Wegovy/Ozempic supply shortage | HIGH | HIGH | Catalent acquisition addresses |
| Lilly tirzepatide competition | MEDIUM | HIGH | First-mover brand recognition |
| Action | Owner | Due Date | Status |
|---|---|---|---|
| Facility construction and validation | Project Team | Per phase | ACTIVE |
| FDA/regulatory submissions | Regulatory | Ongoing | ACTIVE |
| Manufacturing process transfer | Operations | Per product | ACTIVE |
| Issue | Severity | Status | Resolution |
|---|---|---|---|
| Wegovy/Ozempic supply | HIGH | ACTIVE | Capacity expansions underway |
| Decision | Date | Rationale | Impact |
|---|---|---|---|
| $4.1B Clayton expansion | Jun 2024 | Largest life science investment in NC | 1.4M sq ft, 1,000 jobs |
| BE&K Building Group selected | Jun 2024 | Design-build and CM for 10+ buildings | 56-acre facility development |
| Catalent acquisition | Dec 2024 | $16.5B for manufacturing scale | Fill-finish capacity globally |
| LEED Gold certification | 2024 | Circular for Zero sustainability | Net-zero environmental impact |
Upcoming Milestones
Dates from official company announcements and regulatory filings